CAMBRIDGE, Mass., Aug. 10 /PRNewswire/ -- Feinstein Kean Healthcare (FKH) announced that its corporate re-branding program for Nabi Biopharmaceuticals , a leading, global biotechnology company, has been chosen as a merit award winner in the ReBrand 100(TM) awards. ReBrand 100(TM) recognizes best practice work in successfully and uniquely repositioning, revitalizing, restructuring and/or re-designing a brand to drive a company's strategic business objectives.
Thomas H. McLain, chairman, chief executive officer and president, Nabi Biopharmaceuticals, stated, "The strength of our Company's communications does not lie in novelty, but in the consistency and high quality with which we apply communications as an integral part of advancing our business objectives. FKH understands this and has helped us successfully elevate our communications program to a new, important and unprecedented level."
Mr. McLain continued, "Our 2004 communications campaign and this award reflect the best practice work we have come to know from our relationship with FKH. Over the past two years, FKH has become a true partner, helping Nabi Biopharmaceuticals drive an innovative, insightful and creative program that has resulted in a richer appreciation of our story, progress and future prospects."
Culminating in 2004, Nabi Biopharmaceuticals shifted from its former role as a plasma-based company to its new life as an innovative, emerging biopharmaceuticals business. The Company grew its revenue significantly, made advances in the clinical development of its products and strengthened its infrastructure. FKH's challenge was to update the old image of Nabi Biopharmaceuticals to ensure that key constituencies perceived the Company as an industry leader.
FKH, in partnership with Weymouth Design of Boston, revitalized Nabi Biopharmaceuticals' corporate brand and graphic identity, including the design and execution of a new logo, corporate website, annual report, and corporate presentation. The results of the campaign, led by FKH's Senior Vice President, Francesca DeVellis, included extensive trade and business press coverage and renewed investor interest. Notably, the campaign was driven by FKH's in-depth and holistic analysis of Nabi Biopharmaceuticals - the culture, the products, the people, the technology, the business strategy, the commercial opportunities and the Company's role as an important contributor to improving human healthcare - clinically and economically.
FKH leveraged its specialized knowledge as a pioneer in biotechnology communications, built over the past 16 years, to capture the Company's new corporate brand and transform the way it communicates to and is perceived by its constituents. This campaign was tailored specifically for Nabi Biopharmaceuticals from the bottom up by applying many disciplines and skills - scientific understanding, communications expertise, connections to and understanding of Wall Street and the press, financial/SEC knowledge, strong program execution, strategic thinking, and creativity.
About Feinstein Kean Healthcare
Feinstein Kean Healthcare, a wholly owned subsidiary of Ogilvy Public Relations Worldwide, specializes in integrated corporate and product communications for life sciences and healthcare companies and organizations. The firm's portfolio of clients includes the full spectrum of emerging therapeutic and technology platform companies; four of the world's five largest pharmaceutical companies; government agencies; and policy organizations. For more information about FKH, visit: www.fkhealth.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The Company is poised to capture large, commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, and kidney disease (nephrology), and opportunistically in nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi- HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and preclinical development. The company filed its Marketing Authorization Application in Europe for its product candidate, StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate Vaccine], in December 2004. The application was accepted for review in January 2005. StaphVAX is currently in a confirmatory Phase III clinical trial in the United States. StaphVAX is designed to prevent the most dangerous and prevalent strains of S. aureus bacterial infections. S. aureus bacteria are a major cause of hospital- acquired infections and are becoming increasingly resistant to antibiotics. The company's other products in development include Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)], an antibody for prevention and treatment of S. aureus infections, NicVAX(TM) [Nicotine Conjugate Vaccine], a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website at: www.nabi.com.
About Weymouth Design
Weymouth Design, founded in 1973, has expertise in all aspects of corporate communications and corporate brand identity. The award-winning firm's capabilities include print, digital media, photography and video. The firm's clients include a range of life sciences, technology/industrial, professional/financial services and consumer/retail companies. For more information, visit: www.weymouthdesign.com.
About ReBrand 100(TM)
ReBrand is the online source for case studies and programs focused on effective rebrands: the repositioning, revitalizing, or redesign of existing brand assets to meet strategic goals.
Ogilvy Public Relations Worldwide